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Aims To date, the therapeutic benefit of revascularization vs. medical therapy for stable individuals undergoing invasive cor-




We examined 15 223 patients without known coronary artery disease (CAD) undergoing CCTA from eight sites and
six countries who were followed for median 2.1 years (interquartile range 1.4–3.3 years) for an endpoint of all-cause
mortality. Obstructive CAD by CCTA was defined as a ≥50% luminal diameter stenosis in a major coronary artery.
Patients were categorized as having high-risk CAD vs. non-high-risk CAD, with the former including patients with at
* Corresponding author: Tel: +1 310 423 4223, Email: james.min@cshs.org
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2012. For permissions please email: journals.permissions@oup.com
European Heart Journal (2012) 33, 3088–3097
doi:10.1093/eurheartj/ehs315
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
least obstructive two-vessel CAD with proximal left anterior descending artery involvement, three-vessel CAD, and
left main CAD. Death occurred in 185 (1.2%) patients. Patients were categorized into two treatment groups: revas-
cularization (n ¼ 1103; 2.2% mortality) and medical therapy (n ¼ 14 120, 1.1% mortality). To account for non-rando-
mized referral to revascularization, we created a propensity score developed by logistic regression to identify
variables that influenced the decision to refer to revascularization. Within this model (C index 0.92, x2 ¼ 1248,
P, 0.0001), obstructive CAD was the most influential factor for referral, followed by an interaction of obstructive
CAD with pre-test likelihood of CAD (P ¼ 0.0344). Within CCTA CAD groups, rates of revascularization increased
from 3.8% for non-high-risk CAD to 51.2% high-risk CAD. In multivariable models, when compared with medical
therapy, revascularization was associated with a survival advantage for patients with high-risk CAD [hazards ratio
(HR) 0.38, 95% confidence interval 0.18–0.83], with no difference in survival for patients with non-high-risk CAD
(HR 3.24, 95% CI 0.76–13.89) (P-value for interaction ¼ 0.03).
Conclusion In an intermediate-term follow-up, coronary revascularization is associated with a survival benefit in patients with
high-risk CAD by CCTA, with no apparent benefit of revascularization in patients with lesser forms of CAD.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Computed tomography † Coronary revascularization † Medical therapy † Coronary artery disease
Introduction
Numerous large-scale clinical studies have observed a distinct sur-
vival benefit for both percutaneous and surgical coronary revascu-
larization when compared with medical therapy in stable patients
with high-risk angiographic coronary artery disease (CAD) as
demonstrated by invasive coronary angiography (ICA).1,2 Recently,
coronary computed tomographic angiography (CCTA) has
emerged as a novel non-invasive alternative for angiographic as-
sessment of CAD extent and severity, with high diagnostic per-
formance when compared with ICA, and prognostic value for
prediction of adverse events based upon CCTA-identified
CAD.3–5 Although the management of patients without obstruct-
ive CAD by CCTA is considered straightforward, little evidence is
available regarding appropriate management of patients who are
found to have high-grade coronary stenoses on CCTA. Whether
CCTA findings can stratify individuals with CAD who may
benefit from coronary revascularization vs. medical therapy
remains unexplored. The goal of the present study was to deter-
mine the relative therapeutic impact of coronary revascularization
vs. medical therapy on survival from a large international, multicen-
tre, observational cohort of patients undergoing CCTA.
Methods
Patients
This study represents 15 223 stable patients without known CAD or
suspected acute coronary syndrome from the CONFIRM Registry
(Coronary CT Angiography EvaluatioN For Clinical Outcomes: An
InteRnational Multicenter Registry), which has been previously
described.6 CONFIRM enrolled consecutive adults ≥18 years of age
between 2005 and 2009 who underwent ≥64-detector row CCTA
for suspected CAD. Eight of 12 centres for which follow-up for coron-
ary revascularization was available are represented in the present study
(Cedars Sinai Medical Center, Los Angeles, CA; Harbor UCLA Medical
Center, Los Angeles, CA; Tennessee Heart and Vascular Institute,
Hendersonville, TN; Capital Cardiology Associates, Albany, NY; Uni-
versity of Munich, Munich, Germany; Ottawa Heart Institute,
Ontario, Canada; Henry Ford Medical Center, Detroit, Michigan;
Yonsei Medical Center, Seoul, Korea; University Hospital, Zurich,
Switzerland; William Beaumont Hospital, Royal Oak, MI; Walter
Reed Armey Medical Center, Washington DC; University Hospital of
Parma, Parma, Italy). Institutional review board approval was obtained
at each centre. Individuals with known CAD, as defined by prior myo-
cardial infarction or prior coronary revascularization, were excluded
from the present study analysis (Figure 1).
Prior to the initiation of the scan, we prospectively collected infor-
mation on the presence of categorical cardiac risk factors in each indi-
vidual.7 Systemic arterial hypertension was defined as a documented
history of high blood pressure or treatment with anti-hypertensive
medications. Diabetes mellitus was defined by diagnosis of diabetes
made previously by a physician and/or use of insulin or oral hypogly-
cemic agents. Dyslipidaemia was defined as known but untreated dys-
lipidaemia, or current treatment with lipid-lowering medications. A
positive smoking history was defined as current smoking or cessation
of smoking within 3 months of testing. Family history of coronary heart
Figure 1 Study flow chart.
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disease was determined by patient query. Symptom presentation was
classified into one of four categories: typical chest pain/dyspnoea; atyp-
ical chest pain; non-cardiac pain or asymptomatic.
Scan protocol and image reconstruction
Coronary computed tomographic angiography scans were performed
on a variety of different scanner platforms (Lightspeed VCT, GE
Healthcare, Milwaukee, WI; Somatom Definition CT, Siemens, Erlangen,
Germany; Somatom Definition Flash CT, Siemens, Ehrlangen, Germany)
in accordance to performance guidelines from the Society of Cardiovas-
cular Computed Tomography (SCCT).8 Imaging of a test-bolus of con-
trast was performed at 2 mm superior to the takeoff of the left main
coronary artery for precise timing of contrast injection. During the
CCTA acquisition, 80–140 cc of iodinated contrast (Isovue 370,
Bracco Diagnostics, Princeton, NJ; Omnipaque, GE Healthcare, Prince-
ton, NJ; Visipaque, GE Healthcare, Princeton, NJ; or Imeron 350;
Bracco Atlana Pharma, Konstanz, Germany) was injected followed by
a 50 cc saline flush. Contrast timing was performed to optimize
uniform contrast enhancement of the coronary arteries. The scan para-
meters were 64× 0.625/0.750 mm collimation, tube voltage 100 or
120 mV, effective 400–650 mA. Dose reduction strategies—including
ECG-gated tube current modulation, reduced tube voltage, and pro-
spective axial triggering—were employed whenever feasible.
Helical or axial scan data were obtained with retrospective or pro-
spective ECG gating, respectively. Images were reconstructed immedi-
ately after completion of the scan to identify motion-free coronary
artery images. Optimal phase reconstruction was assessed by compari-
son of different phases, if available, and the phase with the least amount
of coronary artery motion was chosen for analysis. Multiple phases
were employed for image interpretation if motion-free images were
different for different arteries. Coronary computed tomographic
angiographys were evaluated by an array of post-processing imaging
techniques, including axial, multiplanar reformat, maximum intensity
projection, and short axis cross-sectional views. In all individuals, irre-
spective of image quality, every arterial segment was scored in an
intent-to-diagnose fashion. If a coronary artery segment was uninter-
pretable despite these multiple techniques, the unevaluable segment
was scored similar to the most proximal segment that was evaluable.
Non-invasive coronary artery analysis by
CCTA
All scans were analysed by level III-equivalent cardiologists or radiolo-
gists with experience interpreting several thousand CCTA scans in
direct accordance with the SCCT guidelines.9 Coronary computed
tomographic angiography interpretation was uniform across all study
sites, with coronary segments visually scored for the presence of cor-
onary plaque using a 16-segment coronary artery model in an
intent-to-diagnose fashion. In each coronary artery segment, coronary
atherosclerosis was defined as tissue structures .1 mm2 that existed
either within the coronary artery lumen or adjacent to the coronary
artery lumen that could be discriminated from surrounding pericardial
tissue, epicardial fat, or the vessel lumen itself. Coronary atheroscler-
otic lesions were quantified for stenosis by visual estimation. Luminal
diameter stenosis severity was scored as none (0% luminal stenosis),
mild (1–49% luminal stenosis), moderate (50–69% luminal stenosis),
or severe (≥70% luminal stenosis). Percent obstruction of coronary
artery lumen was based on a comparison of the luminal diameter of
the segment exhibiting obstruction to the luminal diameter of the
most normal appearing site immediately proximal to the plaque. In
instances in which plaque was highly calcified, 2D oblique images
were also visualized without maximal intensity projection (i.e.
0.625–0.75 mm isotropic voxel resolution) or multiplanar reformats
with cross-sectional views to minimize partial volume averaging arte-
fact of calcium.
For purposes of classification for per-vessel analyses, we considered
four arterial territories: left main artery (LM); left anterior descending
(LAD) artery; left circumflex (LCx) artery; and right coronary artery
(RCA). Obstructive CAD in the diagonal branches, obtuse marginal
branches, and posterolateral branches was considered as part of the
LAD, LCx and RCA system, respectively. The posterior descending
artery was considered as part of the RCA or LCx system, depending
upon the coronary artery dominance. A ≥50% stenosis in the left
main artery was considered obstructive in all models. Extent of ob-
structive CAD was defined by ≥50% stenosis in 0, 1, 2, or 3 coronary
artery vessels.
Per-segment analysis was judged for individual coronary artery seg-
ments that included the LM artery; proximal, mid-, and distal LAD; first
and second diagonal branch; proximal and distal LCx; first and second
obtuse marginal branch; proximal, mid-, and distal right coronary
artery; left and right posterolateral artery; and posterior descending
artery. Coronary artery disease severity was calculated using clinical
coronary artery plaque scores, as we have previously described.7,10
For assessment of the severity of CAD, a modified Duke CAD
index, combining the location and degree of stenosis, was employed
that we have previously demonstrated to provide incremental and
linear gradations of prognostic risk of incident death in relations to
extent and severity of CAD. Within the Duke CAD index, eight
groups are present: Group 0 ¼ No CAD; Group 1 ¼ ≥1 segment
with 1–49% stenosis; Group 2 ¼ ≥2 segments with 1–49% stenosis
AND at ≥1 proximal segment with any stenosis; Group 3 ¼ ≥1
segment with 50–69% stenosis; Group 4 ¼ ≥2 segments with 50–
69% stenosis OR ≥1 segment with ≥70% stenosis; Group 5 ¼ ≥3
segments with 50–69% stenosis OR ≥2 segments with ≥70% stenosis
OR pLAD with ≥70% stenosis; Group 6 ¼ ≥3 segments with ≥70%
stenosis OR ≥2 segments with ≥70% stenosis AND pLAD with
≥70% stenosis); Group 7 ¼ left main with ≥50% stenosis. Based
upon these gradations and their associated prognosis, patients were
also categorized into two separate groups that included non-high-risk
CAD (Groups 0–4) and high-risk CAD (Groups 5–7).
Further, we examined the extent of CAD as determined by the
number of major epicardial coronary vessels that possessed obstruct-
ive CAD (as defined by ≥50% stenosis), ranging from no CAD to
three-vessel CAD. If a left main coronary stenosis of ≥50% was
present, this was considered for the purposes of the study analysis
equivalent to three-vessel CAD.
Statistical analysis and study design
SAS 9.2 (www.sas.com, Cary, NC) or SPSS 12.0 and 17.0 (www.SPSS
.com, Chicago, IL) were used for all statistical analyses. Categorical
variables are presented as frequencies and percentages. Continuous
variables are presented as means+1 standard deviation or medians
(interquartile range) when appropriate. Variables were compared
with x2 statistic for categorical variables and by Student’s unpaired
t-test or Wilcoxon non-parametric test where appropriate for con-
tinuous variables. We further examined individuals undergoing post-
CCTA coronary revascularization vs. medical therapy alone. Given
the observational nature of the present cohort study, we employed
statistical measures to account for non-random allocation of individuals
to medical therapy or coronary revascularization. Post-test coronary
revascularization was defined as having occurred in the first 90 days
following CCTA, and was selected based upon our prior published
studies that have indicated that this timeframe is consistent with treat-
ment based upon test findings (i.e. within a general episode of care)
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while revascularization occurring after this time occurs as a result of a
worsening clinical state.11 Post-test medical therapy vs. revasculariza-
tion was adjusted via a propensity score that accounted for the deci-
sion to refer an individual for revascularization and allocated patient
assignment to treatment type in a manner similar to that for a rando-
mized clinical trial, as we have previously described.12 In order to ac-
complish this, we performed a two-step process that entailed the
development of the propensity score followed by execution of a multi-
variable Cox proportional hazards model that included the propensity
score. The propensity score was developed using a logistic regression
model that summarized predictors of referral of patients to revascular-
ization vs. medical therapy. All potential factors known to influence this
referral pattern were include a priori into the propensity score devel-
opment with significant factors retained in the final model. All variables
demonstrating significance (using P, 0.10 for interaction) were
included in the final propensity score, which represented a summary
measure for prediction of referral for revascularization.
Time to death from all causes was calculated using univariate Cox
proportional hazards models to determine the relationship of
medical therapy vs. coronary revascularization for time of freedom
from death by all causes. We also performed a multivariable
risk-adjusted Cox proportional hazards model. This approach con-
trolled for the effect of baseline differences in the comparator
cohorts as well as the impact of non-randomized treatment allocation
on survival. A hazard ratio and 95% confidence interval was calculated
from the Cox models. Model overfitting procedures were carefully
considered. A two-tailed P-value of ,0.05 was considered statistically
significant.
Follow-up
The primary endpoint was time to death from all causes. Follow-up
procedures were approved by all study centres’ institutional review
boards. Death status for non-US centres was gathered by clinical
visits, telephone contacts, and questionnaires sent by mail; with verifi-
cation of all reported events by hospital records or direct contact with
a patient’s attending physician. Death status for US centres was ascer-
tained either by query of the Social Security Death Index or by
scripted interview by experienced physician and/or nurse study
investigators.
Results
Clinical characteristics of the study
cohort
Baseline characteristics are listed in Table 1. Comparing with
patients undergoing medical therapy, patients undergoing coronary
revascularization were older, more likely to be male, more likely to
possess CAD risk factors including hypertension, diabetes, dyslipi-
daemia, smoking, and family history of CAD. Patients undergoing
revascularization also possessed greater rates of typical angina, ob-
structive CAD, and higher pre-test likelihood of CAD.
Clinical treatment and events
Individuals were followed for a median of 2.1 years (interquartile
range 1.4–3.3 years). Among individuals undergoing revasculariza-
tion (n ¼ 1109), most (n ¼ 1103) had the procedure within the
first 90 days. More patients undergoing post-CCTA coronary
revascularization did so by percutaneous coronary intervention
(PCI) (n ¼ 913; 82.8%) when compared with coronary artery
bypass surgery (CABG) (n ¼ 228; 20.7%), with a small minority
undergoing both PCI and CABG (n ¼ 38, 3.5%). Coronary revas-
cularization rates differed in relation to the extent and severity
of CAD, with 3.8% (534 of 14 111), and 51.2% (569 of 1.112) of
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Table 1 Baseline characteristics of the study groups
Medical therapy Revascularization P-value
n 14 120 1103
Male sex, % (n) 54 (7599) 71 (783) ,0.0001
Hypertension, % (n) 47 (6570) 59 (647) ,0.0001
Diabetes mellitus, % (n) 12 (1700) 24 (261) ,0.0001
Hypercholesterolaemia, % (n) 54 (7533) 67 (734) ,0.0001
Smoking, % (n) 16 (2239) 22 (244) ,0.0001
Family history of CAD, % (n) 29 (4020) 39 (421) ,0.0001
Typicality ,0.0001
Asymptomatic, % (n) 31 (4116) 24 (251)
Non-cardiac angina, % (n) 5 (659) 5 (50)
Atypical angina, % (n) 36 (4774) 29 (305)
Typical angina or dyspnoea, % (n) 29 (3862) 42 (445)
Age, mean (range) 56 (18–92) 63 (29–94) ,0.0001
Extent of stenosis by CCTA ,0.0001
Non-obstructive (,50%), % (n) 87 (12 284) 13 (139)
Obstructive (≥50%), % (n) 13 (1836) 87 (964)
Pre-test likelihood of CAD, median (range) 0.46 (0.003–0.943) 0.67 (0.003–0.943) ,0.0001a
aDifferences tested using Wilcoxon test.
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revascularization occurring in patients with non-high-risk CAD and
high-risk CAD, respectively (P, 0.01).
During follow-up, a total of 185 deaths occurred (1.22% of the
entire population), with the majority of deaths occurring in the first
year (n ¼ 85), followed to a lesser degree during the second year
(n ¼ 53) and more than 2 years (n ¼ 44) after testing. As stratified
by treatment method, death occurred in 1.14% (161 of 14 120) of
those treated with medical therapy and 2.18% (24 of 1103) of
those treated with coronary revascularization
Propensity score
From the logistic regression analysis, the most significant predic-
tors of referral to coronary revascularization were presence of ob-
structive CAD and pre-test probability of CAD as calculated by the
method of Diamond and Forrester13 Table 2. Family history of
CAD was significantly associated with referral to revascularization
and was thus included in the propensity score. At a 0.10 signifi-
cance level for interactions, the interaction between pre-test prob-
ability of CAD and obstructive CAD was significant (P ¼ 0.0344)
and was also included in the final propensity score model (C
index 0.91, x2 ¼ 1248, P, 0.0001).
Survival analysis
The final Cox regression model for prediction of all-cause mortal-
ity included the following variables: age (linear and non-linear);
male gender; hypertension; dyslipidaemia; diabetes; angina typical-
ity; smoking; treatment type (revascularization vs. medical
therapy); CAD severity categorized as non-high-risk CAD vs. high-
risk CAD; the interaction of treatment and CAD severity; and the
propensity score predicting referral to revascularization Table 3.
When checking the proportional hazards assumptions for the
Cox model, a significant time effect was observed to interact
with CAD severity. To account for this, two additional terms
were added to the final Cox regression model; the first was a
two-way interaction between time and CAD severity, the
second was a three-way interaction between time, CAD severity,
and treatment. The final hazard ratios estimate the effect of treat-
ment (revascularization vs. medical therapy) at different levels of
CAD severity, and are given at the median follow-up time of 2.1
years.
The univariate relationship between CAD severity and death
with respect to revascularization vs. medical therapy can be
observed in Figures 2 and 3. Figure 2 depicts the overall mortality
of high-risk and non-high-risk CAD patients in the revascularization
and medical therapy groups. A survival benefit with revasculariza-
tion was seen for patients with high-risk CAD, whereas patients
with less severe CAD demonstrated lower mortality rates when
treated with medical therapy alone. Figure 3 illustrates the mortality
rate with the respective treatments by the extent of CAD as
defined by number of major epicardial vessels with obstructive
CAD. In patients with single-vessel CAD, no significant difference
in mortality was observed between those undergoing and not
undergoing revascularization. However, an observational survival
benefit for those undergoing revascularization was observed in
patients with two-vessel disease, with a trend towards benefit
noted for patients with three-vessel disease.
Univariate Cox proportional hazards models of survival in rela-
tionship to revascularization or medical therapy can be seen in
Table 3. In multivariable Cox proportional hazards models, when
compared with medical therapy, revascularization was associated
with a survival advantage for patients with high-risk CAD
(hazards ratio 0.38, 95% confidence interval 0.18–0.83), with no
difference in survival for patients with non-high-risk CAD (HR
3.24, 95% CI 0.76–13.89) at the median follow-up period
(P-value for interaction of revascularization and high-risk CAD
and time ¼ 0.03). Using the final Cox model, we also evaluated
subgroups to determine whether any particular cohort benefited
more from coronary revascularization Figure 4. Improvement in
survival was evident for all subgroups when high-risk CAD was
treated with revascularization with no specific subgroup benefiting
substantially more than another.
Discussion
The present results of this large multinational registry of patients
without known CAD undergoing CCTA provide evidence that
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Table 2 Logistic regression model predicting referral to revascularization
Variable b coefficient (95% CI) x2 P-value
Intercept 23.48 (23.68 to 23.28) 1177.43 ,0.0001
Family history of CAD 0.1848 (0.03–0.34) 5.6449 0.0175
DF pre-test probablility 0.3749 (0.18–0.57) 14.7235 0.0001
Obstructive CAD – 1110.59 ,0.0001
Normal 1 Reference Reference
Non-obstructive 20.3437 (20.57 to 20.12) 8.9508 0.0028
Obstructive CAD 2.8367 (2.64–3.03) 792.3851 ,0.0001
DF probability vs. Obstructive CAD – 6.7387 0.0344
Normal vs. DF_probability 1 Reference Reference
Non-obstructive vs. DF_probability 20.2872 (20.51 to 20.06) 6.2515 0.0124
Obstructive CAD vs. DF_probability 20.1778 (20.38 to 0.02) 3.1141 0.0776
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95% CI P-value Hazard
ratio
95% CI P-value
Male sex 0.9 0.66–1.22 0.502 1.17 0.85–1.61 0.3326
Hypertension 2.31 1.66–3.22 ,0.0001 1.8 1.28–2.54 0.0007
Dyslipidaemia 0.67 0.50–0.91 0.0104 0.67 0.49–0.91 0.01
Diabetes 1.77 1.25–2.50 0.0013 1.83 1.29–2.60 0.0007
Age, linear 1.09 1.07–1.11 ,0.0001 0.87 0.81–0.97 0.002
Age vs. age, non-linear 1.001 1.001–1.001 ,0.0001 1.002 1.001–1.002 ,0.0001
Typicality of chest pain
Asymptomatic 1 Reference Reference 1 Reference Reference
Non-cardiac 1.61 0.88–2.95 0.1215 1.31 0.71–2.42 0.3834
Atypical 0.46 0.29–0.71 0.0006 0.47 0.30–0.74 0.0012
Typical/dyspnoea 1.21 0.84–1.72 0.3029 1.1 0.77–1.59 0.5943
Smoker 1.72 1.22–2.41 0.0018 2.2 1.56–3.12 ,0.0001
Treatment (revasc vs. medical Tx) 0.69 0.42–1.12 0.1308 N/A N/A 0.4484
High-risk vs. low-risk CAD 1.49 0.95–2.34 0.0836 N/A N/A 0.5821
Revasc vs. high-risk CAD N/A N/A 0.0899 N/A N/A 0.0161
High risk vs. time N/A N/A 0.3652 N/A N/A 0.4477
High risk vs. time vs. early revasc 0.1179 0.03
Revasc vs. medical Tx (high-risk CAD at 2.1 year follow-up) 0.52 0.30–0.89 0.38 0.18–0.83
Revasc vs. medical Tx (low-risk CAD at 2.1 year follow-up) 0.87 0.46–1.64 3.24 0.76–13.9
Propensity 51.6 21.9–121.4 ,0.0001 4.84 1.41–16.6 0.012
Figure 2 Observed death rates for patients with obstructive coronary artery disease undergoing medical therapy (medical Tx) or revascular-
ization (revasc) by high-risk vs. non-high-risk coronary artery disease.
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Figure 3 Observed death rates for patients undergoing medical therapy (medical Tx) or revascularization (revasc) by obstructive coronary
stenosis for one-, two-, or three-vessels.
Figure 4 Predicted all-cause mortality rates in patients treated with medical therapy vs. coronary revascularization as stratified by
non-high-risk coronary artery disease, and high-risk coronary artery disease. Exploratory analyses that do not reach statistical significance.
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stable patients with high-risk CAD—inclusive of those with two-
vessel obstructive CAD with proximal left anterior descending
artery involvement, three-vessel obstructive CAD, and obstructive
left main CAD—experience a survival benefit from undergoing
revascularization when compared with standard medical therapy
alone. In contradistinction, those with lesser forms of CAD—
which represent the predominant majority of individuals undergo-
ing CCTA—do not experience any difference in survival by under-
going revascularization. These results were evident in observed
rates of mortality following revascularization as well as after adjust-
ment for the assignment of individuals to revascularization vs.
medical therapy. On the basis of the final Cox models, the benefits
for revascularization in the high-risk CAD subset are suggestive of
generalizability across a myriad of patient subgroups.
Our group has previously reported on the prognostic value of
CCTA-identified CAD extent and severity, and has observed
increased risk of death and major adverse cardiac events14 for
CCTA measures of high-risk CAD, obstructive CAD, and even
for milder forms of non-obstructive CAD.7,15–17 The prognostic
value of CCTA-identified CAD is incremental to traditional mea-
sures of CAD risk assessment—including being additive to mea-
sures of left-ventricular function, myocardial perfusion, coronary
artery calcium scores, and clinical evaluation—and generalizable
across an array of patient subgroups including those without and
with known CAD, diabetics, women, and asymptomatic
patients.17–22 In this article, we sought to further determine
whether there exists a threshold of angiographic CAD above
which revascularization might hold a relative therapeutic advantage
over medical therapy alone. Given the large-scale international
multisite nature of the CONFIRM registry, these results extend
prior studies by examining the potential therapeutic benefit of
CCTA-guided decision making. Future studies examining
whether CCTA can improve appropriate referral to cardiac cath-
eterization with intended coronary revascularization now appear
warranted.
Recently, large-scale registries and randomized controlled trials
(RCT) have suggested that ischaemia-guided revascularization may
be superior to angiographically guided revascularization for reduc-
tion of events.12,23,24 In particular, the recent FAME, or Fractional
Flow Reserve vs. Angiography for Multivessel Evaluation, trial
demonstrated a higher survival for patients undergoing revascular-
ization based upon lesion-specific assessment of coronary artery
stenosis haemodynamic significance.25 Similarly, a prior large-scale
registry from our own group has revealed that revascularization
based upon a function of % ischaemic myocardium as judged by
non-invasive myocardial perfusion testing may identify individuals
who may benefit from coronary revascularization over medical
therapy alone.12 The results of the present study do not conflict
with these prior landmark studies, and whether ischaemia-guided
revascularization is superior to angiographically guided revascular-
ization by CCTA is beyond the scope of the study. Rather, given
the recent designation of CCTA by American College of Cardi-
ology Appropriate Use Criteria as an appropriate alternative to
functional stress for symptomatic individuals with suspected
CAD, these data may be useful for practitioners to identify thresh-
olds at which cardiac catheterization with intended revasculariza-
tion after CCTA may be considered reasonable or not.26
On its surface, the results of the present study may appear in-
congruous with recent RCTs that have challenged the notion
that the addition of coronary revascularization to optimal
medical therapy (OMT) is superior to OMT alone in stable patients
with angiographically obstructive CAD.27,28 Particularly germane to
the present discussion are the results of the COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggressive Drug Evalu-
ation) trial, which evaluated 2287 patients with angiographic ob-
structive CAD who were assigned to revascularization plus OMT
vs. OMT alone. At a 4.6-year follow-up, no differences were
noted between groups for MACE events or angina-related
quality of life. And indeed, in the present study, for the vast major-
ity of patients with CCTA-identified CAD—including those with
angiographically obstructive CAD—no survival benefit was
observed for those undergoing coronary revascularization vs.
medical therapy alone. However, for a small minority of patients
undergoing CCTA who were identified as having high-risk CAD
(7.3%; 1112 of 15 223), a survival benefit from revascularization
was observed. The propitious outcomes following revasculariza-
tion in patients with angiographically high-risk CAD may be
explained by differences in the CONFIRM and COURAGE
cohorts. By design, the COURAGE trial systematically excluded
patients with obstructive left main CAD and may have been
affected by unobserved negative selection biases for patients
with more high-risk forms of angiographic CAD.29 In contrast,
the present study assessed the outcomes of patients across the
entire range of CAD severity—including those with high-risk
CAD—without pre-defined selection criteria. Further, the
present study design was an observational one, with no mandated
post-test treatments and thus, medical regimens and medical com-
pliance are unknown. In this regard, the patients in our registry are
assumed to have achieved usual rather than OMT, which may have
served to heighten the outcome disparities between the revascu-
larization and medical therapy groups. In this real world compara-
tive effectiveness study, whether the outcomes of patients with
high-risk CAD taking an OMT regimen could be improved by
revascularization cannot be properly tested. Given the observa-
tional nature of this study, all of its results should be considered
hypothesis-generating rather than hypothesis-proving; future ran-
domized trials further exploring the present findings should be
performed to corroborate the present findings.
The present results harmonize with prior large-scale registries
that have demonstrated a similar hazards reduction for death in
patients with angiographically high-risk CAD treated with revascu-
larization. Mark et al.2 examined 9263 patients referred for invasive
angiography during a 7-year period. In this cohort, a growing
benefit for revascularization was noted for patients with increas-
ingly severe CAD, with an almost 40% lower rate of cardiovascular
death in patients with three-vessel obstructive CAD undergoing
coronary artery bypass grafting in favour of medical therapy. Simi-
larly, the Coronary Artery Surgery Study examined 11 508 patients
for sudden death, comparing those treated with medical therapy
vs. coronary revascularization by surgical methods.1 In this
cohort with high-risk CAD, a 25% lower rate of sudden death
was observed in patients undergoing revascularization. Both of
these studies identified the most favourable outcomes of patients
with high-risk CAD to be related to surgical, as opposed to
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percutaneous revascularization. Importantly, these investigations
were performed in an era that preceded contemporary stent tech-
nologies. In the current study, we did not specifically examine the
mortality differences associated with revascularization by percu-
taneous methods vs. CABG because to do so would have compro-
mised statistical power and because angiographic data was not
available for review. However, given the recent large-scale RCTs
that have demonstrated a similar survival advantage among patients
treated with surgical vs. percutaneous revascularization methods,
we believe that combination of these methods into a single revas-
cularization category is both contemporary in its scope as well as
scientifically justified.30–32
This study is not without limitations. While the patient cohorts
represent those from a diversity of clinical practice sites and coun-
tries, all study results are subject to the limitations of observational
data. In particular, unobserved confounders and selection and/or
referral biases may have affected our study results. It is notable
to mention, however, that we performed careful statistical model-
ling to account for patterns of referral to coronary revasculariza-
tion vs. medical therapy, in a manner that simulated an RCT
design.12 Further, we aimed to examine those patients who under-
went revascularization as a response to CCTA findings and chose a
90-day window after CCTA performance to define early post-test
revascularization. This window of time was chosen as lengthier
periods of time after testing generally represent clinical worsening
that exceeds the warranty of an episode of care for which the ori-
ginal test was ordered.11,33,34
Notably, in this prospective multicentre observational cohort
study, post-CCTA treatment regimens were not mandated. Our
study results may have differed, particularly in the high-risk CAD
subset, if OMT had been mandated; future randomized studies
addressing this issue may be warranted. Further, it should be
noted that we examined baseline characteristics—including CAD
risk factors—as binary variables, rather than as continuous ones.
Thus, the duration of CAD risk factor presence and the severity
of the risk remain unknown. Finally, we examined all-cause mortal-
ity as a primary endpoint, given its unparalleled clinical importance
and freedom from ascertainment bias. Nevertheless, revasculariza-
tion is not expected to affect rates of non-cardiac deaths and the
relative therapeutic impact of revascularization vs. medical therapy
specifically on cardiac death alone or on sudden cardiac death
remains unknown.
Conclusion
In an intermediate-term follow-up of 15 223 patients without
known CAD undergoing CCTA from an international multicentre
observational cohort study, coronary revascularization in patients
with high-risk CAD was associated with significantly lower rates
of all-cause mortality when compared with medical therapy
alone. In contrast, no apparent benefit of revascularization was rea-
lized for patients with lesser forms of CAD. These observational
findings may be potentially useful as hypothesis-generating data
upon which future randomized trials can be considered.
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